These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12041788)

  • 1. In-vitro activity of cefpodoxime proxetil (RU 51807): a comparative disk diffusion study on isolates from geriatric patients.
    Ottomano C; Frugoni S; Berlusconi A; Miseferi G; Mattina R; Anelli M
    J Chemother; 1991 Jan; 3 Suppl 1():62-5. PubMed ID: 12041788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro study to compare sensitivity of amoxicillin+clavulanic acid and cefpodoxime+clavulanic acid among beta-lactamase positive clinical isolates of gram-positive and gram-negative pathogens.
    Pal RB; Pal P; Jain S; Kulkarni KP
    J Indian Med Assoc; 2008 Aug; 106(8):545-8. PubMed ID: 18975519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparative antibacterial activity of cefpodoxime, cefuroxime and cefaclor against strict anaerobic bacteria].
    Dubreuil L; Derriennic M; Sedallian A
    Pathol Biol (Paris); 1990 May; 38(5):343-6. PubMed ID: 2367150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [RU 51807 (cefpodoxime proxetil). In vitro and in vivo antibacterial activity of a new orally administered active cephalosporin].
    Chantot JF; Mauvais P
    Pathol Biol (Paris); 1991 Jan; 39(1):17-27. PubMed ID: 1901403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients.
    Fulton B; Perry CM
    Paediatr Drugs; 2001; 3(2):137-58. PubMed ID: 11269640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Comparative study of the antibacterial activity of cefpodoxime against enterobacteria producing beta lactamases].
    Siebor E; Cordin X; Delpech N; Duez JM; Kazmierczak A
    Pathol Biol (Paris); 1990 May; 38(5):331-5. PubMed ID: 2367149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of pharmacokinetics/pharmacodynamics of cefdinir, cefpodoxime proxetil and cefaclor against common bacteria of community acquired infections].
    Xiao YH; Gao L; Li Y; Lü Y; Liu J; Liu Y
    Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(22):1867-71. PubMed ID: 15631795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.
    Frampton JE; Brogden RN; Langtry HD; Buckley MM
    Drugs; 1992 Nov; 44(5):889-917. PubMed ID: 1280571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Microbiological evaluation of cefpodoxime proxetil.
    Wiedemann B; Luhmer E; Zühlsdorf MT
    Drugs; 1991; 42 Suppl 3():6-12. PubMed ID: 1726210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of cefpodoxime and ten other cephalosporins against gram-positive cocci, Enterobacteriaceae and Pseudomonas aeruginosa, including beta-lactamase producers.
    Wiedemann B; Luhmer E; Zühlsdorf MT
    Infection; 1991; 19(5):363-9. PubMed ID: 1800378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models.
    Liu P; Rand KH; Obermann B; Derendorf H
    Int J Antimicrob Agents; 2005 Feb; 25(2):120-9. PubMed ID: 15664481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Jones RN; Sader HS; Fritsche TR; Pottumarthy S
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of cefpodoxime proxetil (U-76,252; CS-807) against Neisseria gonorrhoeae.
    Schaadt RD; Yagi BH; Zurenko GE
    Antimicrob Agents Chemother; 1990 Feb; 34(2):371-2. PubMed ID: 2109583
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefpodoxime proxetil--a new oral cephalosporin.
    Med Lett Drugs Ther; 1992 Nov; 34(884):107-8. PubMed ID: 1435506
    [No Abstract]   [Full Text] [Related]  

  • 15. In vitro activity of cefpodoxime proxetil (U-76,252; CS-807) against clinical isolates of Branhamella catarrhalis.
    Sarubbi FA; Verghese A; Caggiano C; Holtsclaw-Berk S; Berk SL
    Antimicrob Agents Chemother; 1989 Jan; 33(1):113-4. PubMed ID: 2496654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of cefpodoxime, a new oral cephalosporin, compared with that of nine other antimicrobial agents.
    Sheppard M; King A; Phillips I
    Eur J Clin Microbiol Infect Dis; 1991 Jul; 10(7):573-81. PubMed ID: 1915400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefpodoxime proxetil: a new, broad-spectrum, oral cephalosporin.
    Chocas EC; Paap CM; Godley PJ
    Ann Pharmacother; 1993 Nov; 27(11):1369-77. PubMed ID: 8286813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical evaluation of cefpodoxime proxetil in patients with dermatological infections.
    Imaizumi T; Ishikawa H; Hashimoto I
    J Chemother; 1995 Nov; 7 Suppl 4():137-41. PubMed ID: 8904135
    [No Abstract]   [Full Text] [Related]  

  • 19. Antibacterial activity of cefpodoxime in vitro.
    Liu YC; Huang WK; Cheng DL
    Chemotherapy; 1997; 43(1):21-6. PubMed ID: 8996737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative in vitro activity of cefpodoxime against anaerobes other than Bacteroides fragilis.
    Werner H; Heizmann WR; Höflsauer M
    Infection; 1991; 19(5):377-9. PubMed ID: 1800380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.